We’re determined to develop powerful medicines, that are effective with the best possible safety profile, for people living with cancer. We’re confident we can do so by harnessing the potential of our proprietary drug discovery platforms.
Chief Scientific Officer
Our oncology pipeline
We have more than a dozen next-generation molecules in the clinic, each with a distinctive mechanism of action against either hematologic malignancies or solid tumors.
Follow the science
Our R&D teams follow the science to find treatments for people living with cancer.
Bolstering the immune system
Our immuno-oncology teams are working on ways to boost the immune system to better detect and attack tumors. And our molecular oncology teams are designing powerful precision drugs to either destroy cancer cells or activate immune cells locally.
Rethinking oncology drug development
Our culture of collaboration empowers our teams to achieve real change for people battling cancer.
- LaMarche MJ (2022) Think Biologically, Act Chemically. J Medicinal Chem; DOI: 10.1021/acs.jmedchem.2c01121
- Manandhar M, Chun E, Romesberg FE (2021) Genetic Code Expansion: Inception, Development, Commercialization. J Am Chem Soc 143:4859-4878; DOI: 10.1021/jacs.0c11938
- Mitra-Kaushik S, Mehta-Damani A, Stewart JJ, et al. (2021) The Evolution of Single-Cell Analysis and Utility in Drug Development. AAPS J 23:98; DOI: 10.1208/s12248-021-00633-6
Page updated August 2023